昊华化工科技集团股份有限公司2025年度持续督导意见——重组进展、业绩承诺及公司治理全面披露
一、重大重组交易顺利完成，资产及股份交割全部到位
2024年6月21日，昊华科技收到中国证监会批复，获准通过发行股份向中化集团、中化资产购买中化蓝天集团有限公司（以下简称“中化蓝天”）100%股权，并非公开发行股份募集配套资金不超过45亿元。此项重组方案已顺利实施，相关资产过户、股份登记及募集资金到账等关键节点均已如期完成：
- 中化蓝天100%股权已于2024年7月18日全部过户到昊华科技名下，成为其全资子公司。
- 发行股份购买资产新增股份197,272,967股，募集配套资金新增股份181,451,612股，至2025年1月8日公司总股本增至1,290,033,705股。
- 募集配套资金到账共计44.99999978亿元，全部以现金方式支付，资金净额44.96949561亿元。
二、业绩承诺全面超额完成，盈利释放大幅优于预期
根据业绩补偿协议，2025年度业绩承诺资产1需实现净利润4.43亿元，实际实现9.71亿元，超额完成4.28亿元。业绩承诺资产2需实现收入分成2,691.33万元，实际完成3,219.45万元。合并口径下净利润承诺为4.46亿元，实际实现10.03亿元，超额完成5.57亿元。
这意味着本次重组注入资产盈利能力极强，远超市场预期，为公司带来强劲业绩弹性和股东回报提升空间。
三、全面履行承诺，控股股东、管理层利益高度绑定
所有重组相关方，包括上市公司及其董监高、控股股东中国中化/中国昊华、交易对方中化集团/中化资产、配套资金认购方，均出具了关于信息真实、合法合规、内幕交易、股份锁定、避免同业竞争、规范关联交易、填补被摊薄即期回报等全方位承诺。
尤其值得关注的是：
- 重组获得股份均锁定36个月，如6个月内公司股价低于发行价则自动延长6个月锁定期。
- 业绩补偿优先以获得股份补偿，不足部分以现金补偿。
- 控股股东、中化集团等明确承诺未来五年内解决潜在同业竞争，并优先注入优质资产。
- 各方承诺如违反相关承诺，需依法承担赔偿责任。
四、主营业务表现亮眼，利润高增长有望持续
2025年度，公司实现营业收入166.89亿元，同比增长19.49%；净利润16.42亿元，同比增长48.60%。
分业务来看，高端氟材料板块毛利同比增长110.82%；高端制造化工材料板块毛利同比增长3.99%；电子化学品板块主导产品销量同比增长28.69%；碳减排业务毛利同比增长5.78%。公司已构建完整的“研发机构+生产基地”研产贯通格局，横向耦合与纵向协同效应明显，产业链集成优势突出。
五、公司治理和信息披露持续规范，投资者权益高度保障
公司严格落实证监会和上交所监管要求，法人治理结构完善，决策科学规范，信息披露真实、准确、完整、及时。独立董事、专门委员会、监事会监督机制健全，有效防范关联交易和利益输送，切实维护全体股东合法权益。
六、无重组方案与实际执行重大差异，风险可控
本次重组实际执行情况与已披露的重组方案无重大差异，所有关键实施环节均已如期完成，未发现对公司经营、治理、资产安全和股东利益产生重大不利影响的事项。
七、投资者须关注的潜在影响与价格敏感信息
- 重组资产盈利能力大幅超预期，合并后净利润倍增，有望带动公司估值提升和股价重估。
- 高比例股份锁定，控股股东利益与公司高度绑定，减持压力极小，彰显长期发展信心。
- 全产业链协同整合、优质资产持续注入预期，未来成长空间广阔，长期投资价值突出。
- 如未来同业竞争解决或更多优质资产注入，将进一步释放公司成长潜力，构成股价向上催化剂。
结论
本次持续督导意见披露的重组进展、业绩兑现、公司治理和业务发展等均对公司基本面和市场预期构成重大利好，对股价有明显正面推动作用，建议投资者重点关注公司后续业绩兑现与产业整合进展。
免责声明：本文仅为新闻解读，不构成投资建议。投资者应独立判断，并注意投资风险。公司信息以公告和正式文件为准。
English Version
Haohua Chemical Technology Group 2025 Supervisory Opinion—Major Asset Restructuring, Performance Commitment & Corporate Governance Unveiled
1. Major Asset Restructuring Successfully Completed; Asset and Share Transfers in Place
On June 21, 2024, Haohua Technology received CSRC approval to purchase 100% equity of Sinochem Lantian Group Co., Ltd. from Sinochem Group and Sinochem Asset via share issuance, and to raise supporting funds up to RMB 4.5 billion via private placement. The restructuring was successfully executed with all major milestones achieved:
- 100% equity of Sinochem Lantian was transferred to Haohua Tech by July 18, 2024, making it a wholly-owned subsidiary.
- 197,272,967 new shares were issued for the acquisition, and 181,451,612 new shares for the private placement, increasing total share capital to 1,290,033,705 by January 8, 2025.
- Supporting funds totaling RMB 4.5 billion were received in full, all in cash, with net proceeds of RMB 4.497 billion.
2. Performance Commitments Substantially Exceeded; Earnings Far Ahead of Expectations
According to the performance compensation agreement, for 2025, Performance Asset 1 was required to achieve RMB 442.75 million in net profit but actually achieved RMB 970.74 million—exceeding by RMB 527.99 million. Performance Asset 2’s required revenue share was RMB 26.91 million, with actual at RMB 32.19 million. Consolidated net profit commitment was RMB 446.05 million, while actual was RMB 1,002.90 million—a beat of RMB 556.85 million.
This demonstrates injected assets are highly profitable and far surpass market expectations, providing strong earnings elasticity and upside for shareholder returns.
3. Comprehensive Commitments; Interests of Controllers and Management Highly Aligned
All parties—including the company, directors, supervisors, senior management, controlling shareholders, transaction counterparties and fund subscribers—gave comprehensive commitments on information authenticity, legal compliance, insider trading, share lock-up, avoidance of competition, regulated related-party transactions, and dilution compensation.
Key points for investors:
- Shares from the restructuring are locked up for 36 months, with an automatic 6-month extension if the stock price is below issue price for 20 consecutive trading days within 6 months.
- Performance compensation is prioritized with shares; any shortfall to be made up with cash.
- Controlling shareholders and Sinochem Group pledged to resolve potential competition and inject quality assets within five years.
- Any violation of commitments will result in legal liability and compensation.
4. Strong Core Business Performance; High Profit Growth Expected to Continue
In 2025, the company achieved revenue of RMB 16.689 billion, up 19.49%, and net profit of RMB 1.642 billion, up 48.60%.
By segment: high-end fluorine materials gross profit grew 110.82%; advanced chemical manufacturing gross profit up 3.99%; electronic chemicals core product sales up 28.69%; and carbon reduction/engineering services gross profit up 5.78%. The company has built an integrated “R&D + manufacturing” model, with pronounced synergy and industry chain advantages.
5. Sound Corporate Governance and Disclosure; Strong Investor Protection
The company strictly complies with regulatory requirements, with a robust governance structure, scientific decision-making, and transparent information disclosure. The independent director and committee system is well established, safeguarding all shareholder interests and preventing related-party risks.
6. No Major Deviation from Announced Restructuring Plan; Risks Well Managed
Actual implementation is fully consistent with the announced plan, with all critical steps completed on schedule. No material negative impact on operations, governance, asset safety, or shareholder interests has been identified.
7. Price-Sensitive and Investor-Relevant Points
- Restructured assets are significantly outperforming, with post-merger net profit more than doubling, likely driving company revaluation and share price upside.
- High lock-up ratio for controlling shareholders ensures strong alignment and minimal selling pressure.
- Industry chain integration and potential for further asset injection support long-term growth and investment value.
- Resolution of competition and new asset injections may further unlock value and act as share price catalysts.
Conclusion
The supervisory opinion’s disclosure on restructuring, performance delivery, governance, and business development is materially positive for fundamentals and market expectations and is likely to have a positive share price impact. Investors should closely track earnings performance and further integration progress.
Disclaimer: This article is for news analysis only and does not constitute investment advice. Investors should make independent judgments and be aware of investment risks. Official company announcements and filings prevail.
